NIH Won't Seize Patents To Cut Price Of Cancer Drug Xtandi
The National Institutes of Health on Tuesday rejected a petition urging the government to lower the price of the prostate cancer drug Xtandi by using so-called march-in rights to take control...To view the full article, register now.
Already a subscriber? Click here to view full article